Provided by Tiger Trade Technology Pte. Ltd.

Phathom Pharmaceuticals

7.69
-0.4700-5.76%
Post-market: 7.830.1390+1.81%19:30 EDT
Volume:2.07M
Turnover:16.38M
Market Cap:622.13M
PE:-6.07
High:8.24
Open:8.00
Low:7.66
Close:8.16
52wk High:18.31
52wk Low:7.66
Shares:80.90M
Float Shares:63.93M
Volume Ratio:1.58
T/O Rate:3.24%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2659
EPS(LYR):-3.0342
ROE:-3489.00%
ROA:-8.80%
PB:-1.81
PE(LYR):-2.53

Loading ...

Phathom Pharmaceuticals completes enrollment in pHalcon-EoE-201 clinical trial

TIPRANKS
·
Jun 23

Phathom Pharmaceuticals Completes Patient Enrollment for Phase 2 Trial of Voquezna

MT Newswires Live
·
Jun 23

Phathom completes enrollment in Phase 2 VOQUEZNA trial for eosinophilic esophagitis in adults

Reuters
·
Jun 23

Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 Phalcon-Eoe-201 Study of Voquezna® (Vonoprazan) in Eosinophilic Esophagitis (Eoe)

THOMSON REUTERS
·
Jun 23

Phathom Pharmaceuticals - Topline Results From Phase 2 Trial Expected in Q4 2026

THOMSON REUTERS
·
Jun 23

Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)

GlobeNewswire
·
Jun 23

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jun 17

Phathom Pharmaceuticals Price Target Maintained With a $26.00/Share by HC Wainwright & Co.

Dow Jones
·
Jun 17

Needham pharmaceuticals analysts hold analyst/industry conference call

TIPRANKS
·
May 27

Phathom Pharma to present at Jefferies Global Healthcare Conference

Reuters
·
May 22

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire
·
May 22

Phathom Pharmaceuticals shareholders elected Class I directors at annual meeting

Reuters
·
May 22

Phathom presents Phase 3 pHalcon-NERD-301 vonoprazan symptom analysis at DDW 2026

Reuters
·
May 20

Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting

GlobeNewswire
·
May 20

Phathom (PHAT) Is Up 9.4% After Reaffirming 2026 Profitability Timeline And Narrowing Q1 Loss

Simply Wall St.
·
May 09

Phathom to highlight VOQUEZNA at DDW annual meeting

Reuters
·
May 01

Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Phathom Pharmaceuticals (PHAT) and Zimmer Biomet Holdings (ZBH)

TIPRANKS
·
May 01

Phathom Pharmaceuticals Signals Strong Growth on Earnings Call

TIPRANKS
·
May 01

Phathom Pharmaceuticals Q1 Adj. EPS $(0.18) Beats $(0.32) Estimate, Sales $58.301M Beat $57.028M Estimate

Benzinga Earnings
·
Apr 30

BRIEF-Phathom Pharmaceuticals Q1 Net Income USD -30.369 Million

Reuters
·
Apr 30